Graduate student of grade 2016, Guangzhou University of Chinese Medicine, No.232, Waihuandong Road, University Town, Panyu District, Guangzhou, Guangdong, China.
Radiation Oncology Department, Guangzhou University of Chinese Medicine Second Affiliated Hospital (Guangdong Provincial Hosiptal of Chinese Medicine), No. 55, Neihuanxi Road, University Town, Panyu District, Guangzhou, Guangdong, China.
Radiat Oncol. 2019 Aug 20;14(1):149. doi: 10.1186/s13014-019-1354-5.
The present prospective study evaluated the safety and efficacy of the rectum following KUSHEN Ningjiaos in cervical cancer. We compared rectal wall changes during brachytherapy with or without KUSHEN Ningjiaos in cervical cancer patients and analyzed the difference in spatial dose distribution, including whole rectum-wall (R-w), anterior rectum-wall (R-a) and posterior rectum-wall (R-p).
One hundred cervical cancer patients with and without KUSHEN Ningjiaos were treated with brachytherapy (600 cGy). The whole R-w was divided into two areas of R-a and R-p, and R-w dose surface map were constructed. The volume of each R-w was compared in patients pre- and post-KUSHEN Ningjiaos.
When the pre- vs. post-KUSHEN groups were compared the volume of R-w increased. In the post-KUSHEN group, a significantly higher proportion of the D2cc of V and V compared with the pre-KUSHEN group showed that the D2cc increased from 532.45 cGy to 564.7 cGy and 533.51 cGy to 565.26 cGy, respectively; however, results demonstrated a decrease in the D2cc of R-p from 260.5 cGy to 240.0868 cGy (P < 0.05). The insertion of KUSHEN Ningjiaos resulted in a reduction of the relative volume of R-p exposed to high doses, and regressive analysis showed that the D-max correlated most strongly with V and D2cc (P < 0.01 and P < 0.05, respectively).
The insertion of KUSHEN Ningjiaos can protect the rectum. KUSHEN Ningjiaos appears to be safe and well tolerated; therefore, we believe that there will be fewer adverse events after brachytherapy for patients.
A multi-center, prospective clinical trial for KUSHEN Ningjiaos was inserted into rectum to reduce the rate of radiation proctitis in three-dimensional brachytherapy of cervical cancer. ChiCTR1900021631 . 2 Mar 2019-Retrospectively registered.
本前瞻性研究评估了宫颈癌患者接受苦参宁胶后直肠的安全性和疗效。我们比较了宫颈癌患者在接受近距离放射治疗时使用或不使用苦参宁胶时直肠壁的变化，并分析了包括整个直肠壁（R-w）、前直肠壁（R-a）和后直肠壁（R-p）在内的空间剂量分布的差异。
将 100 例接受苦参宁胶或不接受苦参宁胶治疗的宫颈癌患者进行近距离放射治疗（600cGy）。将整个 R-w 分为 R-a 和 R-p 两个区域，并构建 R-w 剂量表面图。比较苦参宁胶使用前后每个 R-w 的体积。
与苦参宁胶使用前相比，苦参宁胶使用后 R-w 的体积增加。在苦参宁胶使用后组中，V 和 V 中的 D2cc 有更高比例的比例显示 D2cc 从 532.45cGy 增加到 564.7cGy 和 533.51cGy 增加到 565.26cGy，而 R-p 的 D2cc 从 260.5cGy 降低到 240.0868cGy（P<0.05）。苦参宁胶的插入导致暴露于高剂量的 R-p 的相对体积减少，回归分析显示 D-max 与 V 和 D2cc 相关性最强（P<0.01 和 P<0.05）。
苦参宁胶的插入可以保护直肠。苦参宁胶似乎是安全和耐受良好的；因此，我们相信宫颈癌近距离放射治疗后不良反应的发生率会降低。
苦参宁胶插入直肠以降低宫颈癌三维近距离放疗中放射性直肠炎发生率的多中心前瞻性临床试验。ChiCTR1900021631. 2019 年 3 月-回顾性注册。
